Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Inhibitors of microsomal triglyceride transfer protein and method|
|Abstract:||Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure ##STR1## wherein R.sup.1 to R.sup.7, Q, X and Y are as defined herein.|
|Inventor(s):||Biller; Scott A. (Hopewell, NJ), Dickson; John K. (Eastampton, NJ), Lawrence; R. Michael (Yardley, PA), Magnin; David R. (Hamilton, NJ), Poss; Michael A. (Lawrenceville, NJ), Sulsky; Richard B. (Franklin Park, NJ), Tino; Joseph A. (Lawrenceville, NJ), Lawson; John E. (Wallingford, CT), Holava; Henry M. (Meriden, CT), Partyka; Richard A. (Neshanic, NJ)|
|Assignee:||Bristol-Myers Squibb Company (Princeton, NJ)|
|Filing Date:||Jul 21, 1997|
|Claims:||1. A method for preventing, inhibiting or treating atherosclerosis; pancreatitis secondary to hypertriglyceridemia; hyperglycemia (1) by causing reduced absorption of dietary fat through MTP inhibition or (2) by lowering triglycerides through MTP inhibition of (3) by decreasing absorptiion of free fatty acids through MTP inhibition; or obesity secondary to malabsorption of dietary fat, or a method of lowering serum lipid levels, cholesterol and/or triglycerides, or preventing and/or treating hyperlipidemia, or hypercholesterolemia in a mammalian species, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound which has the structure ##STR734## wherein R.sup.1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl wherein alkyl has at least 2 carbons, heteroarylalkyl wherein alkyl has at least 2 carbons, cycloalkyl, or cycloalkylalkyl, all optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from halo, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl; |
R.sup.5 and R.sup.6 are independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, all optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, alkyl, alkoxy, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, heteroarylalkyl, alkylthio, arylthio; with the proviso that when R.sup.5 is CH.sub.3, R.sup.6 is not hydrogen; and
pharmaceutically acceptable salts thereof.
2. The method as defined in claim 1 where the compound employed is
N-1-(3,3-diphenylpropyl)-4-piperidinyl]-N-methyl-benzamide, and the monhydrochloride salts of each thereof.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.